Immortalized Mammalian Cell Panels for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for pre-clinical drug development using cells from single individuals or transformed cell lines are limited in predicting compound activity and toxicity in humans, as they do not accurately represent the in vivo situation, leading to high attrition rates and costs due to late-stage failures of drug candidates.
Innovation Solution
Development of panels comprising immortalized mammalian cell samples from multiple healthy and diseased donors across different age classes and tissue types, including kidney, liver, blood, and skin cells, to create a more representative in vitro testing environment for drug efficacy and toxicity assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary cells are used in assays, then the cells reflect the in vivo situation more accurately, but the cells have limited life span due to telomere shortening, limiting reproducibility
Solution Approach 1:
The patent segments the cell panel into multiple independent cell lines, each derived from different donors and immortalized independently. This allows the panel to maintain representativeness while ensuring continuous availability through multiple replicable sources, overcoming the limited lifespan of individual primary cell cultures.
Solution Approach 2:
The patent applies preliminary immortalization to primary cells before they are exhausted by telomere shortening. By introducing hTERT expression early in the cell culture process, the cells are pre-equipped with extended replicative potential, allowing them to maintain both their primary cell characteristics and extended lifespan for reproducible assays.
2Productivity
If transformed cell lines are used in assays, then the cells are available in unlimited amounts, but the cells have properties that are not representative for the in vivo situation
Solution Approach 1:
The patent applies local quality by selectively immortalizing specific primary cell types (hepatocytes, kidney cells, blood cells, endothelial cells, skin cells) while maintaining their tissue-specific functional characteristics. Each cell line retains the local functional properties of its origin tissue while gaining the proliferative capacity needed for unlimited availability.
Solution Approach 2:
The patent changes the key parameter of cellular replicative potential through controlled hTERT expression, transitioning cells from finite lifespan to immortal status without fundamentally altering their phenotypic characteristics. This parameter change enables unlimited cell availability while preserving in vivo representativeness.
3Device complexity
If cells from a single individual are used in assays, then the assay setup is simple, but the information gained is of limited value for predicting compound activity and toxicity in humans
Solution Approach 1:
The patent creates a universal cell panel where each cell line serves multiple functions: representing different human genetic backgrounds, providing diverse tissue types, and enabling various assay applications. The panel collectively captures human physiological variability while maintaining individual cell lines that are relatively simple to handle.
Solution Approach 2:
The patent merges multiple cell lines from different donors and tissue types into a coordinated panel system. This combination preserves the genetic and phenotypic diversity needed for predictive accuracy while organizing the complexity into a manageable, standardized panel that can be used systematically in drug development assays.
Data Source
AI summary
Panels of mammalian cell samples, kits and methods of use thereof. The panels comprise samples or sets of samples of immortalized primary cells, obtained from different tissues and organs of healthy and/or diseased donors. The cell panels are useful in assays for testing effects of drug candidates, e.g. for activity and toxicity.